Here is executive compensation for the CEOs of publicly traded, U.S.-based gastroenterology companies.
Total compensation information was compiled from the most recent proxy statements filed with the SEC through their online database. The date of the filing is listed under the company. The companies are presented alphabetically.
AbbVie — Richard Gonzalez
2014: $22 million
2015: $20.81 million
2016: $20.97 million
As of March 20, 2017
Allergan Pharmaceuticals — Brenton Saunders
2014: $36.61 million
2015: $21.56 million
2016: $4.13 million
As of March 24, 2017
Boston Scientific — Michael Mahoney
2014: $10.52 million
2015: $11.59 million
2016: $12.02 million
As of March 28, 2017
Exact Sciences Corp. — Kevin Conroy
2014: $3.05 million
2015: $5.65 million
2016: $3.19 million
As of April 28, 2017
Gilead Sciences — John Milligan
2014: $8.26 million
2015: $8.27 million
2016: $13.93 million
As of March 27, 2017
Ironwood Pharmaceuticals — Peter Hecht, PhD
2014: $2.25 million
2015: $4.12 million
2016: $4.24 million
As of April 18, 2017
Johnson & Johnson — Alan Gorsky
2014: $24.98 million
2015: $23.79 million
2016: $26.87 million
As of March 15, 2017
Merck — Kenneth Frazier
2014: $25.02 million
2015: $24.20 million
2016: $21,78 million
As of April 10, 2017
Synergy Pharmaceuticals — Gary Jacobs, PhD
2014: $2.55 million
2015: $4.21 million
2016: $3.08 million
As of June 2, 2017
Valeant Pharmaceuticals — Joseph Papa
2016: $62.71 million
Valeant Pharmaceuticals — former CEO J. Michael Pearson
2016: $11.97 million
2015: $141.57 million
2014: $10.37 million
As of March 23, 2017
More articles on gastroenterology:
FDA grants molecular test for intestinal bacteria 510(k) clearance — 3 insights
Some stage III colorectal cancer may only need three months of chemotherapy — 5 study insights
GI leader to know: Dr. John Weippert of NEO Gastroenterology and Endoscopy Center